Navigation Links
eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
Date:4/23/2008

PHILADELPHIA, April 23 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it will release its 2008 first quarter results for the period ended March 31, 2008 on Monday, May 5,2008 after the market closes. After the release, the Company will host a conference call at 5:00 PM ET later that day.

For the conference call interested participants should dial 800-322-5044 when calling within the United States or 617-614-4927 when calling internationally along with pass code 13961971. There will be a playback available as well. To listen to the playback, please call 888-286-8010 when calling within the United States or 617-801-6888 when calling internationally. Please use pass code 12540628 for the replay.

This call is being webcast by Thomson Financial and can be accessed at eRT's web site at http://www.ert.com . The webcast may also be accessed at Thomson's Institutional investor website at http://www.streetevents.com. The webcast can be accessed for up to one year on either site.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com ) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.

Contact:

Richard Baron Robert East

eResearchTechnology, Inc. Westwicke Partners, LLC

215-282-5566 410-321-9652


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
2. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
3. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
4. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
5. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
6. Derma Sciences Announces Agreement With MedAssets for MEDIHONEY(TM) Wound & Burn Dressings
7. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
8. Avigen, Inc. Announces First Quarter 2008 Earnings Conference Call
9. Ceregene Announces Two Key Additions to Leadership Team
10. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
11. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):